SGK1 in the kidney: disrupted sodium transport in diabetes and beyond by Hills, Claire E. et al.
SGK1 in the Kidney: Disrupted Sodium Transport in
Diabetes and Beyond
Claire E Hills1, Rosemary Bland2 and Paul E Squires2
Affiliations: 1Department of Infection, Immunity and Inflammation, Leicester Medical School, Leicester, UK and 2Biomedical
Research Institute, Department of Biological Sciences, University of Warwick, Coventry, UK
A B S T R A C T
Renal complications of diabetes can be severe; however, the mechanisms that underlie the development and
progression of diabetic nephropathy are poorly understood. Recent evidence suggests that the serum- and
glucocorticoid-induced kinase-1 (SGK1) may be key to this process. SGK1 expression and function are increased in
models of diabetes, and polymorphisms of the SGK1 gene are associated with type 2 diabetes mellitus. A key regulator of
sodium transport within the renal epithelium of the distal nephron, SGK1 was originally isolated as a glucocorticoid-sensitive
gene that regulated the epithelial sodium channel (ENaC; also known as the sodium channel, non-voltage-gated 1,
SCNN1). It is now apparent that SGK1 modulates sodium reabsorption by a number of sodium transporters/channels
throughout the length of the nephron including the Na+/H+ exchange isoform 3 (NHE3), the Na+Cl2 co-transporter (NCC),
and the Na+/K+-ATPase. In addition, SGK1 is regulated by a diverse range of factors including insulin, glucose, intracellular
calcium, transforming growth factor-b1, flow rate, and osmolality. This brief review examines the evidence supporting an
involvement of SGK1 in diabetic nephropathy and discusses how dysregulated sodium transport may account for the
development of secondary hypertension associated with the condition. Furthermore, the article examines how aberrant
SGK1 expression and activity may be responsible for the cellular changes seen in the damaged nephron.
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INTRODUCTION
Diabetic nephropathy is the most common cause of
endstage renal disease and the requirement for renal
replacement therapy. The condition is characterized
by both structural and functional disturbances includ-
ing renal hypertrophy, fibrosis, altered glomerular
filtration rate, glomerular hypertension, proteinuria,
and systemic hypertension [1–3]. Of the mechanisms
that underlie progressive renal damage, dysregulated
Na+ reabsorption is an area that has received con-
siderable attention and is linked to the development of
hypertension in diabetes. Serum- and glucocorticoid-
induced kinase-1 (SGK1) is one of the key regulators of
Na+ reabsorption in the nephron. In models of diabetic
nephropathy, insulin and glucose have been shown to
stimulate the expression and phosphorylation of
SGK1, and SGK1 polymorphisms are also associated
with type 2 diabetes mellitus (T2DM) [4–8].
Furthermore, in models of T2DM, signaling molecules
upstream of SGK1 including protein kinase C (PKC),
diacylglycerol (DAG), Ca2+, and transforming growth
factor beta (TGF-b), all show increased expression.
This minireview examines SGK1-mediated Na+ reab-
sorption and discusses the consequences of disturbed
SGK1 activity and the consequential rise in Na+
reabsorption, in addition to commenting on the
development of those complications associated with
diabetic nephropathy.
SGK1
The serum and glucocorticoid kinase-1 (SGK1) is a
serine/threonine kinase, originally cloned as an aldos-
terone-responsive gene [9, 10]. A number of other roles of
SGK1 have also been identified including regulation of
apoptosis, ion transport, and cellular differentiation
(reviewed in [11]). Expressed in a variety of tissues
including the kidney, eye, liver, heart, pancreas, skeletal
muscle, and brain, SGK1 expression is regulated through
gene transcription and protein degradation, while
kinase activity is dependent on phosphatidylinositol-3-
kinase (PI3-K) activity and subcellular localization [8,
12–14]. These diverse regulatory mechanisms allow
SGK1 to respond to numerous stimuli via cell-type
specific pathways [15]. Three SGK1 splice variants have
been identified, and it is likely that these also dictate
cell-specific functions [16]. In addition to SGK1, two
closely related isoforms (80% amino acid identity), SGK2
and SGK3, have also been identified [17].
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SGK1 is predominantly localized to the distal region
of the nephron, where it is found in the thick
ascending limb of the loop of Henle, distal convoluted
tubule, and the cortical collecting duct [18]. Present in
the cytosol and co-localized with mitochondria under
basal conditions [19–21], high glucose or serum evokes
a translocation of the kinase to the nucleus [20, 22]. It
is also associated with the Na+/K+-ATPase in the
basolateral membrane [18].
SGK1 and the Regulation of ENaC-mediated
Na+ Transport
Sodium reabsorption is critical in maintaining blood
volume and is central to blood pressure control.
Defects in the regulation of Na+ transport underlie
all of the known inherited forms of hypertension, and
disturbed Na+ transport is likely to be responsible for
the development of secondary hypertension associated
with diabetes [23]. Sodium is reabsorbed along the
entire length of the nephron by a number of apical
transporters [24, 25]. However, it is in the distal
nephron and collecting duct where the fine control of
Na+ reabsorption occurs under the auspices of the
renin–angiotensin–aldosterone system. Key to this
process is the epithelial sodium channel (ENaC). The
ENaC (now also known as sodium channel, non-
voltage-gated 1; SCNN1) is a member of the ENaC/
degenerin gene family [26]. It is an apical amiloride-
sensitive channel that facilitates Na+ transport across
the epithelium in a wide variety of tissues including
renal tubules, distal colon, skin, lungs, and eyes [13,
14, 27]. Although five ENaC subunits have been
cloned, a-, b-, c-, d-, and e-ENaC, the formation of a
functional channel appears to require only the a-, b-,
and c- subunits, although recent studies have high-
lighted additional potential interactions with the d-
subunit [28, 29].
Liddle’s syndrome, an autosomal dominant form of
arterial hypertension characterized by salt sensitivity,
hypokalemia, and low aldosterone and renin levels, is
associated with activating mutations in the b- and c-
subunits of the ENaC [30–32]. In contrast, loss of
function mutations result in pseudohypoaldosteronism
type I (PHA-1), a condition associated with salt
wasting, hyperkalemia, metabolic acidosis, and hypo-
tension [33, 34]. ENaC expression is increased by
glucose, and mineralocorticoid receptor antagonists
are effective in reducing renal damage in models of
type 1 and 2 diabetes [35–37].
Aldosterone-stimulated Na+ reabsorption in the
collecting duct and distal colon occurs by increasing
the rate of Na+ entry through the ENaC [27]. When
aldosterone levels are low, ENaC is reportedly con-
fined to a vesicular pool [38]. It is proposed that the
rapid response to aldosterone indicates that early
responses are dependent on the action of existing
ENaCs. An important regulator of this process is
SGK1. Stimulation of SGK1 by aldosterone causes
phosphorylation of SGK1 at serine 422 and threonine
256 via the two downstream 3-phosphoinositide (PIP3)-
dependent kinases PDK2 and PDK1 [39, 40]. SGK1
then binds to and phosphorylates Nedd4-2 (neural
precursor cell-expressed, developmentally downregu-
lated gene 4 isoform), a ubiquitin ligase that directs
proteasome-mediated degradation of ENaCs and inhi-
bits cell surface expression of ENaCs [41, 42].
Therefore, phosphorylation of Nedd4-2 by SGK1
promotes apical membrane localization of the ENaC,
inhibits ENaC degradation, and stimulates ENaC
transcription [43, 44]. Interestingly, this also induces
ubiquitination and degradation of SGK1 [45]. In the
absence of SGK1, the association of Nedd4-2 and ENaC
induces channel retrieval from the plasma membrane
and subsequent proteasomal degradation (reviewed in
[46]). In Liddle’s syndrome, binding of Nedd4-2 to the
ENaC is impaired [47]. This effect is augmented by
reduced Nedd4-2 protein expression as a consequence
of a low salt diet or raised aldosterone [48].
Genetic variants of the SGK1 gene correlate with
slightly increased blood pressure [49, 50]. However, it is
interesting to note that the effects of SGK1 on salt
wasting and blood pressure are not as severe as seen in
either mineralocorticoid or ENaC mutants [51, 52]. This
may be explained by studies that have indicated that
SGK1–Nedd4-2 interactions are not the sole regulators
of ENaC function. While aldosterone increases SGK1-
mediated Nedd4-2 phosphorylation, it does so to a lesser
extent than SGK1 phosphorylation [53]. Likewise,
studies in SGK1 knockout mice have indicated that
ENaC-mediated changes in blood pressure are not
solely mediated by SGK1 (reviewed in [11]). Under
normal dietary conditions, lack of SGK1 has little effect
on salt or fluid retention. However, when fed a low salt
diet, SGK12/2 mice are unable to retain sufficient Na+
to maintain their blood pressure [54]. Similarly, in
SGK12/2 mice fed a high salt diet, blood pressure was
not increased [55, 56]. More recently, it has been shown
that, in SGK12/2 mice, ENaC processing, but not
activity, is attenuated [57].
SGK1 in the Proximal Tubule
To date, the majority of studies have focused on the
role of SGK in ENaC-mediated Na+ reabsorption in the
collecting duct, and little is known about the role of
SGK in the proximal tubule, a major site of glycemic
injury. The principal route by which Na+ is reabsorbed
in this region of the nephron is through the Na+/H+
exchange isoform 3 (NHE3), and experiments in NHE3
knockout mice have confirmed that it also mediates
blood pressure [58]. Several studies have confirmed
that the expression of NHE3 is stimulated by SGK1 in
response to high glucose [59–61]. In addition, SGK1
has also been shown to increase proximal tubular cell
proliferation and reduce cell apoptosis [62]. These
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effects are, in part, mediated through the epidermal
growth factor receptor (EGFR) [62]. It is known that
the glucose-mediated increased in the synthesis of
angiotensin II in the proximal tubule increases NHE3-
mediated Na+ reabsorption in diabetic nephropathy
[63], and Stevens et al recently demonstrated that this
response is also regulated by SGK1 [63].
SGK1 and Cell Volume Regulation
Renal epithelial cells have developed a range of
mechanisms to regulate osmotically induced cell
volume changes. A volume-regulated isoform of SGK
(hSGK), sensitive to hypertonic cell shrinkage, med-
iates the hyperosmotic induction of SGK1 transcription
[64, 65]. Activation of this pathway in response to
hypertonic cell shrinkage is mediated via p38 mitogen
activated protein kinase (MAPK) with phosphorylated
levels of p38 detected 1–2 h after hyperosmotic induc-
tion [66]. Furthermore, application of pharmacological
inhibitors of p38 MAPK significantly reduced the
induction of SGK1 expression in response to hyperto-
nicity [65]. Glucosuria will result in an osmotic diuresis,
leading to high urine flow, and hyperosmotic urine will
cause cell shrinkage of renal epithelial cells. These
changes activate SGK1, increasing ENaC-mediated Na+
reabsorption, water uptake, and chloride channel
expression, thereby restoring cell volume [66, 67].
SGK1 also alters the expression and insertion of the
glucose transporters, GLUT1 and SGLT1, into cell
membranes and increases glucose transport [59, 68–
70]. Metabolism of intracellular glucose to sorbitol will
increase intracellular osmolarity [71]. Likewise, it has
been shown that SGK1 stabilizes the myo-inositol
transporter (SMIT1) in the plasma membrane [72]. The
accumulation of myo-inositol and sorbitol will instigate
an osmotic cell volume increase, which would in turn
initiate a Ca2+-dependent cell volume decrease. This is
likely to be mediated by increased TRPV4 (a mechan-
osensitive transient receptor potential channel), a Ca2+-
permeable channel that responds to numerous stimuli
including increased flow and cell swelling and initiates
a concomitant reduction in SGK1 activity [73, 74].
Elevated levels of cytosolic calcium in proximal and
distal tubular cells have been linked to hyperglycemia
[20, 75, 76], and cell swelling in the proximal tubule is
also associated with increased intracellular Ca2+ [77].
Mechanical stimulation (a surrogate form of osmotic
stress) of cells of the human collecting duct (HCD
cells) evokes a rapid, TRPV4-mediated increase in
[Ca2+]i, which propagates to adjacent cells via gap
junctions [76]. This response counteracts the hyper-
osmotic induction of SGK. However, in diabetes,
sustained expression of SGK1 and TRPV4 may com-
promise this counter-regulatory mechanism. A rise in
[Ca2+]i from constitutive TRPV4 action will further
induce both SGK1 and a-ENaC expression, exacerbat-
ing aberrant renal Na+ handling.
SGK1 and TGF-b1
The molecular and cellular events that give rise to
both structural and functional complications of dia-
betic nephropathy include the release of a number of
different growth factors and cytokines. Among these
regulators is transforming growth factor beta (TGF-b).
A ubiquitous cytokine that has a broad spectrum of
biological functions in a variety of cell types, of the
three TGF-b isoforms (b1, b2, and b3), TGF-b1 is
thought to be the principal mediator of diabetic
complications [78–82]. TGF-b1 initiates its cellular
response by binding to its distinct receptor, TGF-b
receptor II (TbRII), which activates the TbRI kinase
prior to phosphorylation of the receptor-regulated
Smads (R-Smads). Activated R-Smads form oligomeric
complexes with the common Smad (Co-Smad). These
oligomeric complexes then translocate into the
nucleus, where they may regulate gene transcription
by binding to DNA directly and acting as transcrip-
tional activators [83]. Alternatively, they may associ-
ate with nuclear transcription factors such as AP-1
[84]. In many cell lines, TGF-b1 positively regulates its
own expression [85]. Autoinduction of TGF-b1 tran-
scription appears to be mediated through binding of an
AP-1 complex to the TGF-b1 promoter [84].
Increased expression of TGF-b1 and its receptor has
been described in experimental models of renal disease
including membranous nephropathy, obstructive
nephropathy, and diabetic nephropathy [20, 86]. In
both human and experimental diabetes, TGF-b1 gene
expression and protein secretion are increased [87].
The resultant phenotypic and morphological changes
arising from this maladaptive TGF-b signaling con-
tribute to the development of renal fibrosis and the
formation of the fibrotic scar, complications that have
recently been shown to be reversed by the exogenous
application of C-peptide, a cleavage product of the pro-
insulin molecule that has numerous renoprotective
effects [88–90]. The increased levels of TGF-b1
observed in hyperglycemia arise from the activation
of key signaling molecules whose expression is
promoted in response to high circulating glucose
levels. These include UDP-N-acetylglucosamine,
PKC, and members of the MAPK pathway. Although
the downstream targets of TGF-b1, which mediate the
pathophysiology of diabetic nephropathy, remain
largely elusive, the cell hypertrophy observed in
response to these elevated levels of circulating TGF-
b1 may in part be mediated by induction of SGK1. A
downstream target of TGF-b1, SGK1 has been shown to
be transcriptionally upregulated by TGF-b1 in various
cell types [5, 20, 91, 92]. Furthermore, both exhibit
elevated levels of expression in response to high
glucose [20]. Studies have demonstrated that augmen-
ted SGK1 expression in response to exogenous TGF-b1
is negated in the presence of a p38 MAPK inhibitor
[91]. This would suggest that activation of SGK1
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transcription via TGF-b1 is mediated by, and reliant
on, activation of the p38 MAPK signaling pathway.
Activation of SGK1 via p38 MAPK occurs as a result
of cross-talk between the TGF-b1 Smad signaling
pathway and the MAPK signaling cascade, thus
suggesting synergy between the induction of SGK1 in
response to either TGF-b1 or hyperosmotic stress [65].
In addition, in the collecting duct, both mechanical
and glucose-evoked increases in cell–cell communica-
tion are TGF-b1 dependent [93]. The ability of TGF-b1
to function as a key transcriptional regulator of SGK1
has led to its implication as a signaling component
whose enhanced expression may exacerbate the cell
hypertrophy associated with the constitutive patho-
physiological induction of SGK1 seen in diabetes.
The role of TGF-b in the kidney is more commonly
associated with the extracellular matrix and its role in
fibrosis [94]. Renal fibrosis is the leading cause of
endstage renal disease in patients with diabetic
nephropathy and, although there are more than a
dozen fibrogenic factors, TGF-b1 is generally consid-
ered to be the major or predominant isoform involved
in the fibrogenic process. While the role of TGF-b2 and
TGF-b3 remains less clear, published studies to date
support a pro-fibrotic role for all three isoforms, with
the upregulation of all three described in both animal
and human models of diabetes [95–98]. The contribu-
tion of TGF-b in the progression of renal fibrogenesis
is highlighted by studies demonstrating that improved
renal function coincides with a reduction in TGF-b
expression, especially that of the b1 and b2 isoforms
[99]. These observations make the pro-fibrotic actions
of TGF-b an ideal target for therapeutic intervention
and have led to a great deal of emphasis being placed
on blockade of the TGF-b pathway [100]. Inhibition of
TGF-b1, TGF-b2, or TGF-b3 by isoform-specific neu-
tralizing antibodies is accompanied by a reduction in
renal scarring and improved kidney function [101–104].
Furthermore, intervention of the downstream signal-
ing effects of TGF-b, through exogenous application of
various agonists including BMP7, HGF and, more
recently, the PPARc agonist troglitazone and C-
peptide, dramatically improves renal function, redu-
cing inflammation and fibrosis [105–108]. However, the
underlying events that mediate TGF-b-induced fibrosis
are complicated, with numerous cell types and multi-
ple signaling pathways together promoting develop-
ment of the fibrotic lesion. SGK1 has been shown to be
expressed in numerous fibrosing tissues including
cases of Crohn’s disease, lung fibrosis, liver cirrhosis,
fibrosing pancreatitis, diabetic nephropathy, and
glomerulonephritis [5, 108–112]. As SGK1 has been
proven to act as a downstream target of TGF-b1, it
seems sensible to suggest that SGK1 may mediate some
of these downstream fibrotic effects. Therapeutic
intervention using the SGK inhibitor, GSK650394,
may inhibit the pro-fibrotic actions of TGF-b1 as
mediated by SGK, and thus unmasks SGK1 as a
potential therapeutic target in amelioration of TGF-
b-induced fibrotic complications [113]. Recent studies
by Stevens et al have shown that SGK1 potentiates the
effect of high glucose on fibronectin formation. In
human fibroblasts, this is dependent on the presence
and abundance of the EGFR [114]. Furthermore,
glucose-evoked changes in SGK1 have been found to
mediate fibronectin formation in diabetic mice [115].
Although both TGF-b2 and TGF-b3 exhibit pro-fibrotic
actions in the kidney, a role for either TGF-b2 or TGF-
b3 in the stimulation of SGK1 in the kidney remains to
be confirmed.
CONCLUDING REMARKS
Expressed in a variety of tissues, SGK is tightly
regulated by numerous signaling cascades. This level
of control enables SGK to participate in a number of
cellular functions that include epithelial transport,
excitability, cell proliferation, and apoptosis.
Although there are three isoforms of SGK, in the
current article, we have focused on SGK1 as localized
to the kidney and have discussed its role in the control
of electrolyte balance via the epithelial sodium
channel (ENaC) and the Na+/K+-ATPase. Studies using
models of salt-sensitive hypertension demonstrate
increased SGK1 expression, and variants of the gene
correlate with elevated blood pressure, which point to
a role for SGK1 in the fine regulation of sodium
reabsorption. However, knockout models of SGK1
suggest that the kinase is not the sole determinant of
ENaC-mediated changes in blood pressure and that
this process relies on a complex interplay of signaling
molecules. Similarly, changes in Na+ reabsorption and
the development of secondary hypertension seen in
diabetes are not limited to alterations in the ENaC.
SGK1 also regulates the NHE3 transporter in the
proximal tubule, suggesting that SGK1 may play a
pivotal role in sodium retention in the proximal
tubule. SGK1 also regulates the expression and
activity of the basolateral Na+/K+-ATPase and the
increase in the Na+Cl– co-transporter (NCC) seen in
animals under salt restriction. These effects are
attenuated in SGK2/2 animals. This suggests that
SGK1 contributes to subtle alterations in the control
of Na+ reabsorption throughout the nephron. Under
normal physiological conditions, these actions will
maintain circulating blood volume and, in conjunction
with TRPV4, also maintain cell volume. In diabetes,
renal epithelial cells are exposed to a number of
signals, including hyperinsulinemia and hyperglyce-
mia, that act to increase SGK1 expression and
function. Furthermore, hyperglycemic-induced TGF-
b1 formation together with flow and osmotically
driven increases in SGK1 provide a link between
poorly controlled plasma glucose and the development
of excess Na+ reabsorption that underlies secondary
hypertension. While SGK1-induced Na+ reabsorption
is clearly important in the pathophysiology of diabetic
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nephropathy, SGK1 also plays a part in fibrosis and
increased proliferation, which further promote the
renal cellular damage seen in diabetes.
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